Omega Alpha SPAC ^{Priced, Nasdaq: OMEG}

We are a newly organized blank check company. While we may pursue a business combination target in any business or industry, we intend to focus on the healthcare or healthcare-related industries, to capitalize on the expertise and capabilities of our management team in order to create long-term shareholder value. In particular, we expect to target North American or European companies in the biotechnology sector where our management team has extensive investment experience. Our sponsor is an affiliate of Omega, a leading international life sciences-focused investment firm with more than $1 billion of investment capital raised as of September 30, 2020. With headquarters in Boston, Massachusetts and a presence in Geneva, Switzerland through its sub-advisory relationship with NeoMed Management, Omega creates and invests in companies that develop drugs and medical devices addressing significant unmet medical needs. Our management team has over 65 years of collective investing experience in the life sciences, led by Otello Stampacchia, our Chief Executive Officer, Michelle Doig, our President, Francesco Draetta, our Chief Financial Officer and Vincent Ossipow, our Chief Scientific Officer, each of whom has significant transactional experience building, operating and investing in the healthcare sector globally.